Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00538343 · ClinicalTrials.gov registry record · Phase 2
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00538343: Clinical Trial Phase 2 study, sponsored by Biogen.
NCT00538343 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00538343, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
Interventions
- DRUG berubicin hydrochloride (RTA 744)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-10-31 |
| Est. Completion | 2009-01-01 |
| Phase | Phase 2 |
Why NCT00538343 stopped before completion
NCT00538343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which berubicin hydrochloride (RTA 744) is the first listed.
NCT00538343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00538343 about?
NCT00538343 is a clinical study titled "RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases". The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
What is the current status of trial NCT00538343?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-10-31. Estimated completion is 2009-01-01.
What interventions are being tested in trial NCT00538343?
The interventions under investigation include: berubicin hydrochloride (RTA 744) (DRUG).
Who is sponsoring clinical trial NCT00538343?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00538343's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy